Trial dedicated to repurposed therapies for COVID-19 wins prestigious international award
Monash University Adjunct Research Professor and Distinguished Alumnus, Craig Rayner, is part of the international team behind the TOGETHER trial, which has been awarded the David Sackett Trial of the Year for 2021.
The award is presented annually by The Society for Clinical Trials, in recognition of the randomised clinical trial published in the previous year that best fulfils a range of selected standards, including improvement to the lot of humankind and the provision of a substantial, beneficial change in health care.
The TOGETHER trial, which is an ongoing study, aims to identify effective repurposed therapies to prevent the disease progression of COVID-19.
Dr Rayner is one of several international collaborators of the trial, which has evaluated repurposed medicines against COVID-19 in Brazil, with the trial leading to numerous publications including in the Journal of the American Medical Association, The Lancet and the New England Journal of Medicine.
“There are many innovations with this study, including its adaptive nature, the successful operationalisation during a pandemic, the use of translational science and clinical pharmacology in informing the study and many more,” said Dr Rayner.
“But what really sets this trial apart is the tenacity of the lead investigators, the clinical operations teams, the statistical teams, the site investigators, clinicians and allied health staff across Minas Gerais and the incredible collaboration and solidarity amongst the entire international TOGETHER trial team.”
On May 16 2022, the Society for Clinical Trials (SCT) will present the David Sackett Trial of the Year award at the SCT’s 43rd Annual Meeting in San Diego, California.
To learn more about the TOGETHER trial visit: https://www.togethertrial.com/